A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation

Trial Profile

A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation; Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Allergan; Ironwood Pharmaceuticals
  • Most Recent Events

    • 09 May 2017 Results published in Ironwood Pharmaceuticals media release.
    • 09 May 2017 Results presented at the Digestive Disease Week 2017
    • 19 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top